New and emerging lipid-modifying drugs to lower LDL cholesterol

por Kosmas, Constantine E, Pantou, Dafni, Sourlas, Andreas, Papakonstantinou, Evangelia J, Echavarria Uceta, Rogers, Guzman, Eliscer
Publicado 2021

Insulin resistance and cardiovascular disease

por Kosmas, Constantine E., Bousvarou, Maria D., Kostara, Christina E., Papakonstantinou, Evangelia J., Salamou, Evdokia, Guzman, Eliscer
Publicado 2023

Safety and Tolerability of PCSK9 Inhibitors: Current Insights

por Kosmas, Constantine E, Skavdis, Andreas, Sourlas, Andreas, Papakonstantinou, Evangelia J, Peña Genao, Edilberto, Echavarria Uceta, Rogers, Guzman, Eliscer
Publicado 2020

Angiopoietin-Like Protein 3 (ANGPTL3) Inhibitors in the Management of Refractory Hypercholesterolemia

por Kosmas, Constantine E, Bousvarou, Maria D, Sourlas, Andreas, Papakonstantinou, Evangelia J, Peña Genao, Edilberto, Echavarria Uceta, Rogers, Guzman, Eliscer
Publicado 2022

The Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio as a Risk Marker for Metabolic Syndrome and Cardiovascular Disease

por Kosmas, Constantine E., Rodriguez Polanco, Shanna, Bousvarou, Maria D., Papakonstantinou, Evangelia J., Peña Genao, Edilberto, Guzman, Eliscer, Kostara, Christina E.
Publicado 2023

Novel Pharmacological Therapies for the Management of Hyperlipoproteinemia(a)

por Kosmas, Constantine E., Bousvarou, Maria D., Papakonstantinou, Evangelia J., Tsamoulis, Donatos, Koulopoulos, Andreas, Echavarria Uceta, Rogers, Guzman, Eliscer, Rallidis, Loukianos S.
Publicado 2023